Amneal Pharmaceuticals In... (AMRX)
| Bid | 7.81 |
| Market Cap | 3.71B |
| Revenue (ttm) | 2.83B |
| Net Income (ttm) | -625K |
| EPS (ttm) | -0.38 |
| PE Ratio (ttm) | -21 |
| Forward PE | 9.67 |
| Analyst | Buy |
| Ask | 8 |
| Volume | 3,510,356 |
| Avg. Volume (20D) | 1,841,720 |
| Open | 7.79 |
| Previous Close | 7.74 |
| Day's Range | 7.17 - 8.02 |
| 52-Week Range | 5.81 - 9.47 |
| Beta | 1.07 |
About AMRX
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation produc...
Analyst Forecast
According to 5 analyst ratings, the average rating for AMRX stock is "Buy." The 12-month stock price forecast is $11.5, which is an increase of 44.11% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
Amneal Pharmaceuticals: Shares Still Feel Significantly UndervaluedAmneal Pharmaceuticals, Inc. seems fundamentally undervalued, with a market cap significantly lower than peers despite similar revenue levels, suggesting potential for substantial stock price apprecia...
